Ethyl Benzoate

Ethyl Benzoate

SCHEMBL3781397

CCOC(=O)c1ccccc1.CCOCC

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
RAB9A P51151 3/20 0.63
NPC1 O15118 2/20 0.63
GAA P10253 2/20 0.63
KMT2A Q03164 4/20 0.62
MEN1 O00255 3/20 0.62
CA12 O43570 1/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
ESR1 P03372 1/20 0.60
CA7 P43166 1/20 0.60
CA9 Q16790 1/20 0.60
ESR2 Q92731 1/20 0.60
CA14 Q9ULX7 1/20 0.60
TSHR P16473 2/20 0.59
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
MAOA P21397 1/20 0.58
ALDH1A1 P00352 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethyl Benzoate SCHEMBL55674 0.94 LMNA (0.70) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL2762273 0.94 LMNA (0.70) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL25388294 0.94 LMNA (0.70) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL28871046 0.92 LMNA (0.68) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL28365249 0.92 LMNA (0.68) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL29554608 0.92 LMNA (0.68) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL30886688 0.92 LMNA (0.68) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL595705 0.92 LMNA (0.68) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL10340677 0.92 LMNA (0.68) LMNASMN1; SMN2RAB9ANPC1GAA
Ethyl Benzoate SCHEMBL1404143 0.92 LMNA (0.68) LMNASMN1; SMN2RAB9ANPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024071313-A1 COSMETIC COMPOSITION AND COSMETIC 株式会社日本触媒 2024-04-04 WO disclosed
US-20240009092-A1 COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID NIPPON SHOKUBAI CO., LTD. (JP) 2024-01-11 US disclosed
EP-3398585-B1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME HAYASHIBARA CO (JP) 2020-02-26 EP disclosed
EP-1600143-B1 SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE HAYASHIBARA CO (JP) 2019-07-10 EP disclosed
US-20190008747-A1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME Hayashibara Co., Ltd. (JP) 2019-01-10 US disclosed
EP-3398585-A1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME Hayashibara Co., Ltd. (JP) 2018-11-07 EP disclosed
US-10111822-B2 External dermal composition for anti-ageing and method for producing the same Hayashibara Co., Ltd. (JP) 2018-10-30 US disclosed
EP-2939657-B1 SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR HAYASHIBARA CO (JP) 2018-08-08 EP disclosed
EP-3143983-A1 EXTERNAL DERMATOLOGICAL FORMULATION COMPRISING SACCHARIDE DERIVATIVE OF ALPHA, ALPHA-TREHALOSE KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2017-03-22 EP disclosed
US-20150342854-A1 EXTERNAL DERMAL COMPOSITION FOR ANTI-AGEING AND METHOD FOR PRODUCING THE SAME Hayashibara Co., Ltd. (JP) 2015-12-03 US disclosed
EP-2939657-A1 SKIN-EXTERIOR ANTI-AGEING COMPOSITION AND PRODUCTION METHOD THEREFOR Hayashibara Co., Ltd. (JP) 2015-11-04 EP disclosed
US-7854922-B2 Skin preparation for external use characterized by containing sugar derivative of α, α-trehalose KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2010-12-21 US disclosed
US-20070003502-A1 Skin preparation for external use characterized by containing sugar derivative of alpha, alpha-trehalose KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2007-01-04 US disclosed
EP-1600143-A1 SKIN PREPARATION FOR EXTERNAL USE CHARACTERIZED BY CONTAINING SUGAR DERIVATIVE OF a,a-TREHALOSE Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) 2005-11-30 EP disclosed
US-5695867-A LAMINATE BODY COMPRISING A BINDER SANDWICHED BETWEEN A CONSTRAINING LAYER AND A VULCANIZED RUBBER; ADHESION, SHAPING LINTEC CORPORATION (JP) 1997-12-09 US disclosed
EP-0340262-A4 SEMI-PERMEABLE MEMBRANES WITH AN INTERNAL DISCRIMINATING REGION 1990-09-26 EP disclosed
WO-1989004206-A1 SEMI-PERMEABLE MEMBRANES WITH AN INTERNAL DISCRIMINATING REGION THE DOW CHEMICAL COMPANY (US) 1989-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240009092-A1 COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID PLIN5, PHOSPHO1, PLIN3 LMNA 2074/4885SMN1; SMN2 4419/4885RAB9A 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.